Literature DB >> 1333889

Expression of a membrane protease enhances presentation of endogenous antigens to MHC class I-restricted T lymphocytes.

L C Eisenlohr1, I Bacik, J R Bennink, K Bernstein, J W Yewdell.   

Abstract

We find that expression of the membrane dipeptidyl carboxypeptidase angiotensin-converting enzyme (ACE) enhances presentation of certain endogenously synthesized peptides to major histocompatibility complex (MHC) class I-restricted cytotoxic T lymphocytes. ACE appears to function only in an intracellular secretory compartment of antigen-presenting cells. ACE-enhanced antigen presentation requires the expression of the putative antigenic peptide transporters, TAP1 and TAP2. These findings demonstrate that a protease can influence the processing of endogenously synthesized antigens and strongly suggest that longer peptides can be transported from the cytosol to a secretory compartment where trimming of antigenic peptides to the lengths preferred by MHC class I molecules can occur if the appropriate protease is present.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1333889     DOI: 10.1016/0092-8674(92)90392-p

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  54 in total

1.  The envelope protein encoded by the A33R gene is required for formation of actin-containing microvilli and efficient cell-to-cell spread of vaccinia virus.

Authors:  R L Roper; E J Wolffe; A Weisberg; B Moss
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

2.  Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide.

Authors:  A Craiu; T Akopian; A Goldberg; K L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

3.  Presentation of a cytosolic antigen by major histocompatibility complex class II molecules requires a long-lived form of the antigen.

Authors:  M Guéguen; E O Long
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

Review 4.  ACE overexpression in myelomonocytic cells: effect on a mouse model of Alzheimer's disease.

Authors:  Maya Koronyo-Hamaoui; Kandarp Shah; Yosef Koronyo; Ellen Bernstein; Jorge F Giani; Tea Janjulia; Keith L Black; Peng D Shi; Romer A Gonzalez-Villalobos; Sebastien Fuchs; Xiao Z Shen; Kenneth E Bernstein
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

5.  Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen.

Authors:  M Wang; P W Chen; V Bronte; S A Rosenberg; N P Restifo
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1995-10

6.  Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen.

Authors:  L M Mylin; R H Bonneau; J D Lippolis; S S Tevethia
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

Review 7.  A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme.

Authors:  Kenneth E Bernstein; Frank S Ong; Wendell-Lamar B Blackwell; Kandarp H Shah; Jorge F Giani; Romer A Gonzalez-Villalobos; Xiao Z Shen; Sebastien Fuchs; Rhian M Touyz
Journal:  Pharmacol Rev       Date:  2012-12-20       Impact factor: 25.468

8.  Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.

Authors:  Steven A Rosenberg; James C Yang; Douglas J Schwartzentruber; Patrick Hwu; Suzanne L Topalian; Richard M Sherry; Nicholas P Restifo; John R Wunderlich; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Linda Gritz; Dennis L Panicali; Donald E White
Journal:  Clin Cancer Res       Date:  2003-08-01       Impact factor: 12.531

9.  Simian virus 40 T antigen as a carrier for the expression of cytotoxic T-lymphocyte recognition epitopes.

Authors:  T M Fu; R H Bonneau; M J Tevethia; S S Tevethia
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

10.  Recombinant Newcastle disease virus as a vaccine vector for cancer therapy.

Authors:  Adam Vigil; Osvaldo Martinez; Mark A Chua; Adolfo García-Sastre
Journal:  Mol Ther       Date:  2008-08-19       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.